US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NovaBridge Biosciences

1.41

+0.03502.55%

Volume:170.35K

Turnover:238.75K

Market Cap:162.98M

PE:-2.13

High:1.42

Open:1.38

Low:1.37

Close:1.37

52wk High:6.79

52wk Low:1.31

Shares:116.00M

Float Shares:64.56M

Volume Ratio:1.25

T/O Rate:0.26%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.6591

EPS(LYR):-0.9225

ROE:-59.10%

ROA:-34.98%

PB:0.81

PE(LYR):-1.52

Loading ...

Overview Company News Filings

Press Release: Novabridge Biosciences to Hold Annual General Meeting on September 8, 2026

Novabridge Biosciences Launches 2026 Omnibus Share Incentive Plan with 11,960,000 Shares Authorized

Poland’s central bank is buying the dip as gold's biggest buyers aren't backing down

Novabridge Biosciences CEO, Director Srishti Gupta Files Initial Beneficial Ownership Statement

Novabridge Biosciences SVP Clinical Development Xu Cong Claire Sells USD 3,991 Common Shares

Novabridge Biosciences Appoints DR. Srishti Gupta as Chief Executive Officer

THOMSON REUTERS

Novabridge Biosciences - Xi-yong (sean) Fu to Step Down as CEO and Support in Advisory Capacity

THOMSON REUTERS

Press Release: Novabridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer

Wuxi XDC Appoints Yuan Fang Joint Company Secretary, Authorized Representative

NovaBridge Biosciences CMO Dennis Phillip Andrew disposes of ordinary shares worth $5,606.04

NovaBridge Biosciences replaces PwC with Deloitte as auditor

NovaBridge Biosciences Gains US FDA Fast Track Status for Gastroesophageal Cancer Therapy

MT Newswires Live

BUZZ-U.S. STOCKS ON THE MOVE-Qualcomm, Robinhood, Mobileye

NovaBridge wins FDA fast track for givastomig combo in first-line HER2-negative metastatic gastric cancer

Novabridge Biosciences - Registrational Phase 3 Trial for Givastomig Expected to Begin as Early as Q4 2026

THOMSON REUTERS

Novabridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line Her2-Negative Metastatic Gastric Cancer

THOMSON REUTERS

Novabridge Biosciences - Detailed Phase 1B Data for Givastomig Expected in H2 2026

THOMSON REUTERS

NovaBridge Biosciences SVP Clinical Development Xu Cong Claire disposes of 3,494 shares for $13,766.36

Hangzhou Capital-backed BrainCo, ChengTian Tech rank in 2026 Future Healthcare 100 list

Companies Like NovaBridge Biosciences (NASDAQ:NBP) Can Afford To Invest In Growth

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/NBP/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBP\",,,,,undefined,":{"symbol":"NBP","market":"US","secType":"STK","nameCN":"NovaBridge Biosciences","latestPrice":1.405,"timestamp":1791563746274,"preClose":1.37,"halted":0,"volume":170345,"delay":0,"changeRate":0.025547445255474394,"floatShares":64563600,"shares":115999216,"eps":-0.6591,"marketStatus":"Trading","change":0.035,"latestTime":"10-09 12:36:31 EDT","open":1.38,"high":1.4188,"low":1.37,"amount":238751.225237,"amplitude":0.03562,"askPrice":1.41,"askSize":1070,"bidPrice":1.4,"bidSize":3092,"shortable":3,"etf":0,"ttmEps":-0.6591,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791576000000},"marketStatusCode":2,"adr":0,"adrRate":2.3,"listingDate":1579237200000,"exchange":"NASDAQ","adjPreClose":1.37,"preHourTrading":{"tag":"盘前","latestPrice":1.4,"preClose":1.37,"latestTime":"09:28 EDT","volume":1861,"amount":2585.4437526,"timestamp":1791552481083,"change":0.03,"changeRate":0.021898,"amplitude":0.020511},"postHourTrading":{"tag":"盘后","latestPrice":1.4,"preClose":1.37,"latestTime":"19:30 EDT","volume":450,"amount":629.28,"timestamp":1791502204861,"change":0.03,"changeRate":0.021898,"amplitude":0.021898},"volumeRatio":1.249406,"impliedVol":1.1763,"impliedVolPercentile":0.5274},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBP\",,,,,undefined,":{"symbol":"NBP","floatShares":64563600,"roa":"-34.98%","roe":"-59.10%","lyrEps":-0.922468,"volumeRatio":1.249406,"shares":115999216,"dividePrice":0,"high":1.4188,"amplitude":0.03562,"preClose":1.37,"low":1.37,"week52Low":1.31,"pbRate":"0.81","week52High":6.79,"institutionHeld":0,"latestPrice":1.405,"committee":0.485824,"eps":-0.6591,"divideRate":0,"volume":170345,"delay":0,"ttmEps":-0.6591,"open":1.38,"prevYearClose":3.98,"prevWeekClose":1.355,"prevMonthClose":1.365,"prevQuarterClose":1.365,"fiveDayClose":1.355,"twentyDayClose":1.59,"sixtyDayClose":1.79},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NBP\",params:#limit:5,,,undefined,":[{"date":"2026-08-20","symbol":"NBP","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787212800000,"name":null,"time":"Pre-MKt","dateTimestamp":1787198400000,"actualEps":null},{"market":"US","date":"2026-04-07","symbol":"NBP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1775534400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-08-20","symbol":"NBP","fiscalQuarterEnding":"2025/06","expectedEps":-0.1,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"pre","actualEps":-0.07},{"market":"US","date":"2025-05-15","symbol":"NBP","fiscalQuarterEnding":"2025/03","expectedEps":-0.07,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.04},{"market":"US","date":"2025-04-03","symbol":"NBP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1743652800000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NBP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1759550400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NBP","date":"2026-10-08","current":-2.131695,"percent":0.974249,"low":-20.276437,"twenty":-14.364301,"median":-3.220459,"eighty":-2.102462,"high":-1.322277,"avg":-7.686424,"sd":6.129265,"marketCap":158918925},"quantilePoints":[{"date":"2025-10-31","current":-13.114792,"twenty":-13.114792,"median":-13.114792,"eighty":-13.114792,"marketCap":524460541},{"date":"2025-11-07","current":-12.077138,"twenty":-13.547148,"median":-12.71126,"eighty":-12.278904,"marketCap":482964762},{"date":"2025-11-14","current":-12.019491,"twenty":-13.114792,"median":-12.278904,"eighty":-12.077138,"marketCap":480659441},{"date":"2025-11-21","current":-12.077138,"twenty":-13.085968,"median":-12.293316,"eighty":-12.077138,"marketCap":482964762},{"date":"2025-11-28","current":-11.068308,"twenty":-13.06291,"median":-12.192433,"eighty":-11.881137,"marketCap":442621643},{"date":"2025-12-05","current":-11.500664,"twenty":-12.688201,"median":-12.077138,"eighty":-11.212426,"marketCap":459911551},{"date":"2025-12-12","current":-11.298898,"twenty":-12.411494,"median":-12.033903,"eighty":-11.287368,"marketCap":451842927},{"date":"2025-12-19","current":-17.342266,"twenty":-12.688201,"median":-12.048315,"eighty":-11.460311,"marketCap":456552482},{"date":"2025-12-26","current":-20.276437,"twenty":-13.287734,"median":-12.077138,"eighty":-11.500664,"marketCap":533797473},{"date":"2026-01-02","current":-17.429853,"twenty":-17.342266,"median":-12.163609,"eighty":-11.512194,"marketCap":458858303},{"date":"2026-01-09","current":-16.597774,"twenty":-17.482405,"median":-12.235668,"eighty":-11.541017,"marketCap":436953007},{"date":"2026-01-16","current":-16.028458,"twenty":-17.394818,"median":-12.365376,"eighty":-11.569841,"marketCap":421965173},{"date":"2026-01-23","current":-17.03571,"twenty":-17.342266,"median":-13.057145,"eighty":-11.587135,"marketCap":448482110},{"date":"2026-01-30","current":-16.116045,"twenty":-17.3773,"median":-13.33097,"eighty":-11.615959,"marketCap":424270994},{"date":"2026-02-06","current":-14.583269,"twenty":-17.342266,"median":-14.495682,"eighty":-11.742783,"marketCap":383919133},{"date":"2026-02-13","current":-14.189126,"twenty":-17.307231,"median":-14.71465,"eighty":-11.823489,"marketCap":373542940},{"date":"2026-02-20","current":-14.539475,"twenty":-17.167091,"median":-14.517578,"eighty":-11.961843,"marketCap":382766222},{"date":"2026-02-27","current":-14.364301,"twenty":-17.03571,"median":-14.408094,"eighty":-12.019491,"marketCap":378154581},{"date":"2026-03-06","current":-15.94087,"twenty":-17.03571,"median":-14.386197,"eighty":-12.048315,"marketCap":419659352},{"date":"2026-03-13","current":-12.875318,"twenty":-16.991917,"median":-14.364301,"eighty":-12.077138,"marketCap":338955631},{"date":"2026-03-20","current":-11.780478,"twenty":-16.948123,"median":-14.316021,"eighty":-12.077138,"marketCap":310132873},{"date":"2026-03-27","current":-11.167368,"twenty":-16.597774,"median":-14.189126,"eighty":-11.788901,"marketCap":293992129},{"date":"2026-04-02","current":-10.773226,"twenty":-16.597774,"median":-14.101539,"eighty":-11.587135,"marketCap":283615936},{"date":"2026-04-10","current":-3.171352,"twenty":-16.387565,"median":-14.057746,"eighty":-11.527134,"marketCap":280157205},{"date":"2026-04-17","current":-3.495376,"twenty":-16.299978,"median":-13.61981,"eighty":-11.287368,"marketCap":308781505},{"date":"2026-04-24","current":-3.23355,"twenty":-16.221149,"median":-13.10038,"eighty":-11.118286,"marketCap":285651804},{"date":"2026-05-01","current":-3.23355,"twenty":-16.203632,"median":-12.875318,"eighty":-11.061844,"marketCap":285651804},{"date":"2026-05-08","current":-2.906268,"twenty":-16.133562,"median":-12.604261,"eighty":-10.634902,"marketCap":256739678},{"date":"2026-05-15","current":-2.513529,"twenty":-16.045975,"median":-12.365376,"eighty":-3.526795,"marketCap":222045127},{"date":"2026-05-22","current":-2.330251,"twenty":-15.993423,"median":-12.293316,"eighty":-3.374936,"marketCap":205854337},{"date":"2026-05-29","current":-2.448072,"twenty":-15.958388,"median":-12.192433,"eighty":-3.235384,"marketCap":216262702},{"date":"2026-06-05","current":-2.356433,"twenty":-15.651833,"median":-12.134786,"eighty":-3.190946,"marketCap":208167307},{"date":"2026-06-12","current":-1.92442,"twenty":-15.393451,"median":-12.062727,"eighty":-3.136675,"marketCap":170003300},{"date":"2026-06-18","current":-2.055333,"twenty":-15.340898,"median":-11.990667,"eighty":-3.100019,"marketCap":181568151},{"date":"2026-06-26","current":-2.094607,"twenty":-15.292725,"median":-11.780478,"eighty":-2.890558,"marketCap":185037606},{"date":"2026-07-02","current":-2.605168,"twenty":-15.231414,"median":-11.587135,"eighty":-2.686334,"marketCap":230140522},{"date":"2026-07-10","current":-2.434981,"twenty":-15.178862,"median":-11.559911,"eighty":-2.610404,"marketCap":215106217},{"date":"2026-07-17","current":-2.343342,"twenty":-15.091275,"median":-11.517717,"eighty":-2.516147,"marketCap":207010822},{"date":"2026-07-24","current":-2.317159,"twenty":-15.012446,"median":-11.399781,"eighty":-2.437599,"marketCap":204697852},{"date":"2026-07-31","current":-2.146972,"twenty":-14.977411,"median":-11.226206,"eighty":-2.42189,"marketCap":189663546},{"date":"2026-08-07","current":-2.22552,"twenty":-14.977411,"median":-11.123574,"eighty":-2.356433,"marketCap":196602456},{"date":"2026-08-14","current":-2.487346,"twenty":-14.84603,"median":-11.068308,"eighty":-2.356433,"marketCap":219732157},{"date":"2026-08-21","current":-1.87904,"twenty":-14.583269,"median":-11.035987,"eighty":-2.356433,"marketCap":220888642},{"date":"2026-08-28","current":-1.865003,"twenty":-14.539475,"median":-10.707535,"eighty":-2.330251,"marketCap":219238518},{"date":"2026-09-04","current":-1.776193,"twenty":-14.495682,"median":-10.598051,"eighty":-2.317159,"marketCap":208798588},{"date":"2026-09-11","current":-1.667648,"twenty":-14.425612,"median":-3.53465,"eighty":-2.290977,"marketCap":196038675},{"date":"2026-09-18","current":-1.608441,"twenty":-14.408094,"median":-3.436465,"eighty":-2.238612,"marketCap":189078722},{"date":"2026-09-25","current":-1.430822,"twenty":-14.37306,"median":-3.364463,"eighty":-2.158755,"marketCap":168198863},{"date":"2026-10-02","current":-1.322277,"twenty":-14.364301,"median":-3.235078,"eighty":-2.139117,"marketCap":155438949},{"date":"2026-10-08","current":-1.35188,"twenty":-14.364301,"median":-3.220459,"eighty":-2.102462,"marketCap":158918925}],"updateTime":1791563791517},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NBP\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2654694037","title":"Press Release: Novabridge Biosciences to Hold Annual General Meeting on September 8, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2654694037","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654694037?lang=en_us&edition=fundamental","pubTime":"2026-07-25 05:00","pubTimestamp":1784926800,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md., July 24, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (\"NovaBridge\" or the \"Company\"), a clinical-stage biopharmaceutical company advancing innovative medicines for ar","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652044324","title":"Novabridge Biosciences Launches 2026 Omnibus Share Incentive Plan with 11,960,000 Shares Authorized","url":"https://stock-news.laohu8.com/highlight/detail?id=2652044324","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652044324?lang=en_us&edition=fundamental","pubTime":"2026-07-17 18:05","pubTimestamp":1784282711,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences launches 2026 omnibus share incentive plan with 11,960,000 shares authorizedNovaBridge Biosciences adopted a 2026 Omnibus Share Incentive Plan effective July 13, 2026, replacing","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nNDL1tMdJX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650134777","title":"Poland’s central bank is buying the dip as gold's biggest buyers aren't backing down","url":"https://stock-news.laohu8.com/highlight/detail?id=2650134777","media":"Kitco","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650134777?lang=en_us&edition=fundamental","pubTime":"2026-07-10 18:05","pubTimestamp":1783677900,"startTime":"0","endTime":"0","summary":"(Kitco News) - While speculators and retail investors have been liquidating their gold holdings, one major pillar of support remains firmly in place, with central banks viewing the current price actio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"kitco_highlight","url":"https://www.kitco.com/news/article/2026-07-10/polands-central-bank-buying-dip-golds-biggest-buyers-arent-backing-down","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.kitco.com/news/article/2026-07-10/polands-central-bank-buying-dip-golds-biggest-buyers-arent-backing-down","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"kitco_highlight","symbols":["OUNZ","DGZ","DUST","GBUG","DBC","IAUM","GLDY","UGL","DZZ","BK4504","GLDM","GLTR","BK4588","IAU","JDST","JNUG","CEF","GDXY","AAAU","FGDL","GLD","SGDM","BGLD","UYM","GDXU","IAUI","SGOL","BAR","RING","YGLD","GDX","BEGS","GLL","PHYS","BTGD","GOAU","DULL","1OZmain","GOLY","PICK","DGP","PPI","NBP","SHNY","KGLD","IGLD","USG","GDXD","GDXJ","XME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650915054","title":"Novabridge Biosciences CEO, Director Srishti Gupta Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2650915054","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650915054?lang=en_us&edition=fundamental","pubTime":"2026-07-09 04:25","pubTimestamp":1783542307,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences CEO, director Srishti Gupta files initial beneficial ownership statementNovaBridge Biosciences filed a Form 3 naming Srishti Gupta as chief executive officer, disclosing her ini","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nNDLb3rm1Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649553169","title":"Novabridge Biosciences SVP Clinical Development Xu Cong Claire Sells USD 3,991 Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2649553169","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649553169?lang=en_us&edition=fundamental","pubTime":"2026-07-08 07:51","pubTimestamp":1783468265,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences SVP Clinical Development Xu Cong Claire sells USD 3,991 common sharesNovaBridge Biosciences SVP, Clinical Development Xu Cong Claire reported a net reduction in ordinary share h","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDLSnybl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Novabridge Biosciences SVP Clinical Development Xu Cong Claire Sells USD 3,991 Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647759583","title":"Novabridge Biosciences Appoints DR. Srishti Gupta as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2647759583","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647759583?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:00","pubTimestamp":1782730801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA1ZJJRB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NBP","BK4539","IVVD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647751383","title":"Novabridge Biosciences - Xi-yong (sean) Fu to Step Down as CEO and Support in Advisory Capacity","url":"https://stock-news.laohu8.com/highlight/detail?id=2647751383","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647751383?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:00","pubTimestamp":1782730801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA1ZJJRB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647756733","title":"Press Release: Novabridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2647756733","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647756733?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:00","pubTimestamp":1782730800,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md., June 29, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (\"NovaBridge\" or the \"Company\"), a clinical-stage biopharmaceutical company advancing innovative medicines for ar","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Press Release: Novabridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646035396","title":"Wuxi XDC Appoints Yuan Fang Joint Company Secretary, Authorized Representative","url":"https://stock-news.laohu8.com/highlight/detail?id=2646035396","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646035396?lang=en_us&edition=fundamental","pubTime":"2026-06-26 17:26","pubTimestamp":1782466014,"startTime":"0","endTime":"0","summary":"WuXi XDC appoints Yuan Fang joint company secretary, authorized representativeWuXi XDC named Yuan Fang joint company secretary, effective June 26, 2026; she also becomes an authorized representative.F","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDL6Y0xcy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK1587","LU0181495838.USD","BK1589","BK1521","LU1794554557.SGD","LU0327786744.USD","LU0708995583.HKD","LU0516423174.USD","LU2039709279.SGD","LU0140636845.USD","LU0516422440.USD","BK1610","LU0052750758.USD","LU0320764599.SGD","BK1161","BK1574","LU1720050803.USD","LU0588546209.SGD","LU0039217434.USD","LU0417516902.SGD","LU1242518931.SGD","LU0979878070.USD","NBP","LU0516423091.SGD","LU0417516738.SGD","LU0307460666.USD","LU1880383366.USD","02268","LU0572944931.SGD","LU2488822045.USD","LU0051755006.USD","LU0456827905.SGD","LU0823426480.USD","LU1688375341.USD","BK1141","LU1242518857.USD","LU3063872942.SGD","SG9999002463.SGD","02137","LU0348825331.USD","LU0348735423.USD","LU0819121731.USD","LU0043850808.USD","LU0359202008.SGD","IE00B0JY6N72.USD","LU0456846285.SGD","LU0516422952.EUR","LU0516422366.SGD","02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645900894","title":"NovaBridge Biosciences CMO Dennis Phillip Andrew disposes of ordinary shares worth $5,606.04","url":"https://stock-news.laohu8.com/highlight/detail?id=2645900894","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645900894?lang=en_us&edition=fundamental","pubTime":"2026-06-23 05:24","pubTimestamp":1782163461,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences Chief Medical Officer Dennis Phillip Andrew sold 8,494 ordinary shares on June 18 at USD 0.66.Holdings fell to 157,941 ordinary shares following the sale.Andrew also acquired 23,695 ordinary shares on June 17 via an equity award transaction.He reported 82,422 restricted share units after the June 17 vesting-related transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 22, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDLbMrgn7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"NovaBridge Biosciences CMO Dennis Phillip Andrew disposes of ordinary shares worth $5,606.04","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644760741","title":"NovaBridge Biosciences replaces PwC with Deloitte as auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=2644760741","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644760741?lang=en_us&edition=fundamental","pubTime":"2026-06-17 04:40","pubTimestamp":1781642455,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences replaced PwC as independent auditor with Deloitte, effective June 16, 2026, for the fiscal year ending Dec. 31, 2026.PwC audit opinions for fiscal 2025 and 2024 were clean, with no adverse opinion, disclaimer, or scope or accounting qualifications.No reported auditor disagreements; the only cited reportable issue was material weaknesses in IT general controls at Dec. 31, 2025 and 2024.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 16, 2026, and is solely responsible for the information cont","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL4jzk5k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643575487","title":"NovaBridge Biosciences Gains US FDA Fast Track Status for Gastroesophageal Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2643575487","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643575487?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:41","pubTimestamp":1781610076,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences  said Tuesday the US Food and Drug Administration granted fast track designation to its experimental therapy, givastomig, in combination with nivolumab and chemotherapy, for certain previously untreated patients with HER2-negative advanced or metastatic gastroesophageal adenocarcinoma.The company said the fast track designation is intended to accelerate the development and regulatory review of therapies that address serious conditions and unmet medical needs.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","BK4139","NBP","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643751790","title":"BUZZ-U.S. STOCKS ON THE MOVE-Qualcomm, Robinhood, Mobileye","url":"https://stock-news.laohu8.com/highlight/detail?id=2643751790","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643751790?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:34","pubTimestamp":1781609654,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Qualcomm, Robinhood, Mobileye Workspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter:","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nL6N42O0S7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015978.USD","BK4551","HIYY","BK4124","LU1496350502.SGD","HOOW","LU0081259029.USD","ROBN","LU1066053197.SGD","LU2065169927.USD","LU1046421795.USD","LU1261432733.SGD","LU2065171402.SGD","HOYY","BK4196","GB00BDT5M118.USD","IE00BGHQDM52.EUR","BK4588","QCMU","SG9999002224.SGD","LU0079474960.USD","BK4598","LU2023250504.SGD","LU1084165304.USD","LU1066051811.HKD","BK4127","BK4080","HIMS","IE00BVYPNQ40.USD","LU1244550577.SGD","LU1244550221.USD","BK4575","BK4581","LU0942090050.USD","BK4157","LU2065171311.SGD","LU1069344957.HKD","HOOX","HIMZ","LU0868494708.USD","LU1035775433.USD","BK4527","QCML","LU1823568750.SGD","LU2247934214.USD","BK4547","LU1917777945.USD","BK4539","HUN","HOOZ","LU1244550494.USD","SG9999015952.SGD","LU2106854487.HKD","LU2065170008.USD","LU1119994496.HKD","LU1861559042.SGD","BK4573","BK4534","BK4141","SG9999002232.USD","BK4512","BK4554","HOOD","SG9999015986.USD","BK4612","IE00BSNM7G36.USD","HMYY","BK4139","HODU","LU1066051498.USD","BK4579","ALVO","BK4604","LU0061475181.USD","QCMD","LU1861558580.USD","BK4231","BK4561","NBP","HOOY","MAC","LU0054578231.USD","LU0868494617.USD","BK4585","SG9999001424.SGD","HIMY","HOII","HOOG","BK4605","BK4532","SG9999015945.SGD","IE00BVYPNP33.GBP","QCOM","HOOI","LU1066051225.USD","BK4515","LU1974910355.USD","BK4098","MBLY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643759457","title":"NovaBridge wins FDA fast track for givastomig combo in first-line HER2-negative metastatic gastric cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2643759457","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643759457?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:01","pubTimestamp":1781607680,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences received FDA Fast Track designation for givastomig with nivolumab and chemotherapy in first-line HER2-negative metastatic GEA.Early-stage findings showed strong anti-tumor activity with manageable tolerability, supporting further development in a biomarker-selected population.A registrational Phase 3 trial is expected to start as early as Q4 2026, setting up the next major value inflection point.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 16, 2026, and is solely responsible for the infor","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL65dnHW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643759675","title":"Novabridge Biosciences - Registrational Phase 3 Trial for Givastomig Expected to Begin as Early as Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643759675","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643759675?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:00","pubTimestamp":1781607601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUA4RYD6F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643575962","title":"Novabridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line Her2-Negative Metastatic Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2643575962","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643575962?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:00","pubTimestamp":1781607601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUA4RYD6F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643275918","title":"Novabridge Biosciences - Detailed Phase 1B Data for Givastomig Expected in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643275918","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643275918?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:00","pubTimestamp":1781607601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUA4RYD6F:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640853921","title":"NovaBridge Biosciences SVP Clinical Development Xu Cong Claire disposes of 3,494 shares for $13,766.36","url":"https://stock-news.laohu8.com/highlight/detail?id=2640853921","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640853921?lang=en_us&edition=fundamental","pubTime":"2026-06-03 06:47","pubTimestamp":1780440460,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences SVP, Clinical Development Xu Cong Claire reported an RSU vesting into 9,382 ordinary shares on May 30, 2026.Xu sold 3,494 ordinary shares on June 1, 2026 at USD 3.94 per share.Directly owned ordinary shares stood at 290,154 following the sale.Directly held restricted share units totaled 32,637 after the vesting transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL7FngBj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"NovaBridge Biosciences SVP Clinical Development Xu Cong Claire disposes of 3,494 shares for $13,766.36","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640393487","title":"Hangzhou Capital-backed BrainCo, ChengTian Tech rank in 2026 Future Healthcare 100 list","url":"https://stock-news.laohu8.com/highlight/detail?id=2640393487","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640393487?lang=en_us&edition=fundamental","pubTime":"2026-06-01 16:09","pubTimestamp":1780301388,"startTime":"0","endTime":"0","summary":"Hangzhou State Capital Investment and Operations reported multiple direct-investment portfolio companies ranked in the “2026 Future Healthcare 100” lists.Innovation devices, intelligent manufacturing Top 100: BrainCo; ChengTian Technology.Innovative drugs, biologics Top 100: Qihan Bio; Linke Pharma; Haichang Bio; Triastek; Kejun Pharma; Lingyi Bio.Health services, industry-chain services Top 100: Ailios; Heiyu Science.Other invested companies cited in the sector: Deepwise AI Lab; Yangli Pharma; Nurotron; I-Mab; Yuyan Pharma.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hangzhou State Capital Investment and Operations Co Ltd published the original content used to generate this news brief on June 01, 2026, and is solely responsible for","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL5rn0qQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638688769","title":"Companies Like NovaBridge Biosciences (NASDAQ:NBP) Can Afford To Invest In Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2638688769","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638688769?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:17","pubTimestamp":1779880679,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbp/novabridge-biosciences/news/companies-like-novabridge-biosciences-nasdaqnbp-can-afford-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nbp/novabridge-biosciences/news/companies-like-novabridge-biosciences-nasdaqnbp-can-afford-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QQQM","SQQQ","FTEC","BK4139","TQQY","NQmain","PSQ","NVIW.SI","QQQA","QQQ","IYW","QQQE","GPIQ","TQQQ","QID","NDX","QQQJ","JEPQ","MNQmain",".IXIC","ONEQ","QQQY","QDTE","TECS","QYLG","QLD","NBP"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":48,"code":"91000000","status":"200"}]}}